Test 2 Treat

Currently Recruiting: Participants

Study Drug/Intervention: Evaluating multifaceted strategies to (1) increase LDL-C testing and appropriate management in the inpatient setting for patients hospitalized for myocardial infarction (MI) or coronary revascularization and (2) increase LDL-C testing, appropriate management, and achievement of guideline-based LDL-C goals in the outpatient setting within six months of discharge.

Anticipated Sample Size: 400 patients

Study Anticipated End Date: July 2025

ClinicalTrials.gov ID:  NCT06471036

What is Test 2 Treat?

Test 2 Treat is an implementation science study that combines an inpatient, hospital-level intervention and an outpatient, patient-level, randomized intervention to improve LDL-C testing and treatment in six participating health systems. It is a project of the CardioHealth Alliance.

Study Objective

To increase LDL-C testing and appropriate management in the inpatient setting for patients hospitalized for a cardiac event, and to increase LDL-C testing, appropriate management, and achievement of guideline-based LDL-C goals in the outpatient setting within six months of discharge.

Inclusion Criteria

1. Age ≥ 18 years old
2. Admitted with Type 1 non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI), and/or percutaneous coronary revascularization.
3. LDL-C level during admission ≥ 70 mg/dL.
4. Primary care clinician and/or cardiologist within the health system (and with access to the same electronic health records) who will manage the patient in the outpatient setting.

Exclusion Criteria

1. Determined to be highly unlikely to survive and/or to continue follow-up in that health system for at least six months (including those on hospice or with significant dementia), as identified by the site investigator.
2. Underwent coronary artery bypass grafting (CABG) (patient would therefore be discharged from surgical service).

Patients over 18 who have been admitted to the hospital with a Type 1 NSTEMI or STEMI and/or percutaneous coronary revascularization who are found to have an LDL-C level during admission greater than or equal to 70mg/dL will be approached for participation in Test 2 Treat.

Duration of Study Participation

Six months

Study Follow-Up

Patients randomized to the intervention arm will receive telephone calls from a "Care Navigator" two to three times during the six months after their event and will be asked to answer some questions about their care.

Louisiana

• Ochsner Health

Minnesota

• Allina Health

North Carolina

• Duke University

Pennsylvania

• University of Pittsburgh Medical Center

Tennessee

• Vanderbilt University Medical Center

Texas

• Baylor, Scott, & White Health

Amgen, Inc.

PI: Neha Pagidipati, MD, MPH

PL: Zach Lampron

Implementation Specialist: Monica Leyva